Causality assessment in drug-induced liver injury using a structured expert opinion process: Comparison to the Roussel-Uclaf causality assessment method

Hepatology

Volumn 51, Issue 6, 2010, Pages 2117-2126

  Rockey, Don C ^a   Seeff, Leonard B ^b   Rochon, James ^c   Freston, James ^d   Chalasani, Naga ^e   Bonacini, Maurizio ^f   Fontana, Robert J ^g   Hayashi, Paul H ^h  

^a UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^b NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES   (United States)

^c DUKE CLINICAL RESEARCH INSTITUTE   (United States)

^d UNIVERSITY OF CONNECTICUT HEALTH CENTER   (United States)

^e INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^f CALIFORNIA PACIFIC MEDICAL CENTER   (United States)

^g UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^h UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMOXICILLIN PLUS CLAVULANIC ACID; ANALGESIC AGENT; ANTILIPEMIC AGENT; ANTINEOPLASTIC AGENT; CENTRAL NERVOUS SYSTEM AGENTS; COTRIMOXAZOLE; HERBACEOUS AGENT; IMMUNOMODULATING AGENT;

ADULT; ARTICLE; CONTROLLED STUDY; DIAGNOSTIC PROCEDURE; FEMALE; HUMAN; INTERMETHOD COMPARISON; LIVER INJURY; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROBABILITY; PROSPECTIVE STUDY; ROUSSEL UCLAF CAUSALITY ASSESSMENT METHOD; STANDARDIZATION; STRUCTURED EXPERT OPINION PROCESS; TOXIC HEPATITIS;

ADULT; AGED; DRUG-INDUCED LIVER INJURY; EXPERT TESTIMONY; FEMALE; HUMANS; MALE; MIDDLE AGED; PROSPECTIVE STUDIES;

EID: 77952702755     PISSN: 02709139     EISSN: 15273350     Source Type: Journal    
DOI: 10.1002/hep.23577     Document Type: Article

References (28)

1. Zimmerman HJ. Drug-induced liver disease. Clin Liver Dis 2000;4:73-96.
2. Sgro C, Clinard F, Ouazir K, Chanay H, Allard C, Guilleminet C, et al. Incidence of drug-induced hepatic injuries: a French populationbased study. HEPATOLOGY 2002;36:451-455. (Pubitemid 34810366)
3. Galan MV, Potts JA, Silverman AL, Gordon SC. The burden of acute nonfulminant drug-induced hepatitis in a United States tertiary referral center [corrected]. J Clin Gastroenterol 2005;39:64-67.
4. Vuppalanchi R, Liangpunsakul S, Chalasani N. Etiology of newonset jaundice: how often is it caused by idiosyncratic drug-induced liver injury in the United States? Am J Gastroenterol 2007;102:558-562.
5. Carey EJ, Vargas HE, Douglas DD, Balan V, Byrne TJ, Harrison ME, et al. Inpatient admissions for drug-induced liver injury: results from a single center. Dig Dis Sci 2008;53:1977-1982.
6. Bissell DM, Gores GJ, Laskin DL, Hoofnagle JH. Drug-induced liver injury: mechanisms and test systems. HEPATOLOGY 2001;33:1009-1013. (Pubitemid 32246655)
7. Liu ZX, Kaplowitz N. Immune-mediated drug-induced liver disease. Clin Liver Dis 2002;6:755-774.
8. Watkins PB, Seeff LB. Drug-induced liver injury: summary of a single topic clinical research conference. HEPATOLOGY 2006;43:618-631.
9. Benichou C. Criteria of drug-induced liver disorders. Report of an international consensus meeting. J Hepatol 1990;11:272-276.
10. Benichou C, Danan G, Flahault A. Causality assessment of adverse reactions to drugs-II. An original model for validation of drug causality assessment methods: case reports with positive rechallenge. J Clin Epidemiol 1993;46:1331-1336. (Pubitemid 23333874)
11. Maria VA, Victorino RM. Development and validation of a clinical scale for the diagnosis of drug-induced hepatitis. HEPATOLOGY 1997;26:664-669.
12. Naranjo CA, Busto U, Sellers EM, Sandor P, Ruiz I, Roberts EA, et al. A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther 1981;30:239-245. (Pubitemid 12149145)
13. Garcia-Cortes M, Lucena MI, Pachkoria K, Borraz Y, Hidalgo R, Andrade RJ. Evaluation of Naranjo adverse drug reactions probability scale in causality assessment of drug-induced liver injury. Aliment Pharmacol Ther 2008;27:780-789. (Pubitemid 351490076)
14. Fontana RJ, Watkins PB, Bonkovsky HL, Chalasani N, Davern T, Serrano J, et al. Rationale, design and conduct of the Drug-Induced Liver Injury Network (DILIN) prospective study. Drug Saf 2009;32:55-68.
15. Hoofnagle JH. Drug-induced liver injury network (DILIN). HEPATOLOGY 2004;40:773.
16. Chalasani N, Fontana RJ, Bonkovsky HL, Watkins PB, Davern T, Serrano J, et al. Causes, clinical features, and outcomes from a prospective study of drug-induced liver injury in the United States. Gastroenterology 2008;135:1924-1934.
17. Fleiss JL, Levin B, Paik MC. Statistical Methods for Rates and Proportions. 3rd ed. New York, NY: John Wiley & Sons; 2003.
18. Danan G, Benichou C. Causality assessment of adverse reactions to drugs - I. A novel method based on the conclusions of international consensus meetings: application to drug-induced liver injuries. J Clin Epidemiol 1993;46:1323-1330. (Pubitemid 23333873)
19. Andrade RJ, Lucena MI, Fernandez MC, Pelaez G, Pachkoria K, Garcia-Ruiz E, et al. Drug-induced liver injury: an analysis of 461 incidences submitted to the Spanish registry over a 10-year period. Gastroenterology 2005;129:512-521. (Pubitemid 41096639)
20. Bjornsson E, Kalaitzakis E, Olsson R. The impact of eosinophilia and hepatic necrosis on prognosis in patients with drug-induced liver injury. Aliment Pharmacol Ther 2007;25:1411-1421. (Pubitemid 46848886)
21. Andrade RJ, Lucena MI, Kaplowitz N, Garcia-Munoz B, Borraz Y, Pachkoria K, et al. Outcome of acute idiosyncratic drug-induced liver injury: long-term follow-up in a hepatotoxicity registry. HEPATOLOGY 2006;44:1581-1588. (Pubitemid 44953663)
22. De Valle MB, Av Klinteberg V, Alem N, Olsson R, Bjornsson E. Drug-induced liver injury in a Swedish University hospital outpatient hepatology clinic. Aliment Pharmacol Ther 2006;24:1187-1195. (Pubitemid 44427506)
23. Aithal GP, Rawlins MD, Day CP. Clinical diagnostic scale: a useful tool in the evaluation of suspected hepatotoxic adverse drug reactions. J Hepatol 2000;33:949-952.
24. Lucena MI, Camargo R, Andrade RJ, Perez-Sanchez CJ, Sanchez De La Cuesta F. Comparison of two clinical scales for causality assessment in hepatotoxicity. HEPATOLOGY 2001;33:123-130. (Pubitemid 32016894)
25. Arimone Y, Begaud B, Miremont-Salame G, Fourrier-Reglat A, Moore N, Molimard M, et al. Agreement of expert judgment in causality assessment of adverse drug reactions. Eur J Clin Pharmacol 2005;61:169-173. (Pubitemid 40768547)
26. Arimone Y, Miremont-Salame G, Haramburu F, Molimard M, Moore N, Fourrier-Reglat A, et al. Inter-expert agreement of seven criteria in causality assessment of adverse drug reactions. Br J Clin Pharmacol 2007;64:482-488. (Pubitemid 47404316)
27. Arimone Y, Begaud B, Miremont-Salame G, Fourrier-Reglat A, Molimard M, Moore N, et al. A new method for assessing drug causation provided agreement with experts' judgment. J Clin Epidemiol 2006;59:308-314. (Pubitemid 43243657)
28. Rochon J, Protiva P, Seeff LB, Fontana RJ, Liangpunsakul S, Watkins PB, et al. Reliability of the Roussel Uclaf Causality Assessment Method for assessing causality in drug-induced liver injury. HEPATOLOGY 2008;48:1175-1183.